CST, 36408S, LRRK2 (E8Z7T) Mouse Monoclonal Antibody

Monoclonal Antibody for studying LRRK2. Validated for Immunohistochemistry (Paraffin). Available in 2 sizes. Highly specific and rigorously validated in-house, LRRK2 (E8Z7T) Mouse Monoclonal Antibody (CST #36408) is ready to ship. Product Usage Information Immunohistochemistry (Paraffin): 1:100 - 1:400 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody . For a carrier free (BSA and azide free) version of this product see product # 39029 . Protocol Available protocols: Immunohistochemistry (Paraffin) Specificity / Sensitivity LRRK2 (E8Z7T) Mouse Monoclonal Antibody recognizes endogenous levels of total LRRK2 protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu1840 of human LRRK2 protein. Background Parkinson's disease (PD), the second most common neurodegenerative disease after Alzheimer's, is a progressive movement disorder characterized by rigidity, tremors, and postural instability. The pathological hallmarks of PD are progressive loss of dopaminergic neurons in the substantia nigra of the ventral midbrain and the presence of intracellular Lewy bodies (protein aggregates of α-synuclein, ubiquitin, and other components) in surviving neurons of the brain stem (1). Research studies have shown various genes and loci are genetically linked to PD including α-synuclein/PARK1 and 4, parkin/PARK2, UCH-L1/PARK5, PINK1/PARK6, DJ-1/PARK7, LRRK2/PARK8, synphilin-1, and NR4A2 (2).Leucine-rich repeat kinase 2 (LRRK2) contains amino-terminal leucine-rich repeats (LRR), a Ras-like small GTP binding protein-like (ROC) domain, an MLK protein kinase domain, and a carboxy-terminal WD40 repeat domain. Research studies have linked at least 20 LRRK2 mutations to PD, with the G2019S mutation being the most prevalent (3). The G2019S mutation causes increased LRRK2 kinase activity, which induces a progressive reduction in neurite length that leads to progressive neurite loss and decreased neuronal survival (4). Researchers are currently testing the MLK inhibitor CEP-1347 in PD clinical trials, indicating the potential value of LRRK2 as a therapeutic target for treatment of PD (5). Alternate Names augmented in rheumatoid arthritis 17; AURA17; Dardarin; leucine rich repeat kinase 2; leucine-rich repeat kinase 2; Leucine-rich repeat serine/threonine-protein kinase 2; LRRK2; PARK8; RIPK7; ROCO2 Specification REACTIVITY: H SENSITIVITY: Endogenous Source/Isotype: Mouse IgG2b kappa